ArticleBMC medicine2025
Risk of Parkinson's disease after human papillomavirus infection: a nationwide cohort study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLittle is known about the association between human papillomavirus (HPV) infection and Parkinson's disease (PD). This study aimed to explore the risk of incident PD following HPV infection.
methodsPatients 40 years or older with HPV infection diagnosed between 1996 and 2013 were included in the case group and were 1:4 matched with controls from the Taiwan National Health Insurance Research Database. A second matched control group of patients with acute respiratory infection (ARI) was also included. The outcome was incident PD, as determined using Cox proportional hazards.
resultsThe study population included 80,318 patients with HPV infection, 322,952 non-HPV infection matched controls, and 80,318 ARI infection matched controls. There were 456 incident PD cases in the HPV group (0.84 per 1000 person-year), 2499 in the control group (0.43 per 1000 person-year), and 655 in the ARI control group (0.45 per 1000 person-year). After adjustment for confounding factors, patients with HPV infection were associated with a 1.25-fold higher risk of incident PD (hazard ratio, 1.25, 95% confidence interval, 1.13 to 1.39) than controls. This finding remains consistent when comparing to the ARI control group and in sensitivity analyses. Stratified by sex, only male patients with HPV infection had a 1.48-fold higher risk of PD compared with the control group (1.28 to 1.71) and a 1.31-fold higher risk of PD compared with the ARI control group (1.09 to 1.59); however, no significant associations were observed in the female patients with HPV.
conclusionsThis study suggests an increased risk of incident PD in patients with HPV infection, especially for males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.